References

1. Phillips GL, Herzig RH, Lazarus HM, et al.: Treatment of relapsed lymphoma with cyclophosphamide, total body irradiation and autologous bone marrow transplantation. N Engl J Med 310:1557-1561, 1984.

2. Phillips GL, Fay JW, Herzig RH, et al.: The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 75:831-838, 1990.

3. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030, 1993.

4. Vose JM, Zhang MJ, Rowlings PA, et al.: Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19:406-413, 2001.

5. Vose JM, Rizzo JD, Tao-Wu J, et al.: Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 10:116-127, 2004.

6. Haioun C, Lepage E, Gisselbrecht C, et al.: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000.

7. Milpied N, Ifrah N, Kuentz M, et al.: Bone marrow transplant for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 73:82-87, 1989.

8. Watts MJ, Sullivan AM, Leverett D, et al.: Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 16:1554-1560, 1998.

9. Brenner MK, Rill DR, Moen RC, et al.: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85-86, 1993.

10. Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al.: Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation—The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 21:3744-3753, 2003.

11. Freedman AS, Neuberg D, Mauch P, et al.: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999.

12. Mathe G, Amiel J, Schwarzenberg L, Cattan A, Schneider M: Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 25:1525-1531, 1965.

13. Mollee P, Lazarus HM, Lipton J: Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma? Bone Marrow Transplant 31:953-960, 2003.

14. Tse WW, Lazarus HM, van Besien K: Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant 34:929-938, 2004.

15. Freytes CO, Loberiza FR, Rizzo JD, et al.: Myeloablative Allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report from the

International Bone Marrow Transplant Registry. Blood 104:3797-3803, 2004.

16. van Besien K, Loberiza FR Jr, Bajorunaite R, et al.: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529, 2003.

17. Dhedin N, Giraudier S, Gaulard P, et al.: Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol 107:154-161, 1999.

18. Toze CL, Conneally EA, Connors JM, et al.: Allogeneic hematopoietic stem cell transplantation (AlloHSCT) for non-Hodgkin's lymphoma (NHL) in Vancouver: 17-year experience of the Leukemia/BMT Program of British Columbia (BC) with related donor (RD) and unrelated (UD) donors [abstract]. Ann Oncol 13(suppl 2):39a, 2002.

19. Juckett M, Rowlings P, Hessner M, et al.: T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. Bone Marrow Transplant 21:893-899, 1998.

20. Stein RS, Greer JP, Goodman S, et al.: Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma. Leuk Lymphoma 41:343-352, 2001.

21. Mitterbauer M, Neumeister P, Kalhs P, et al.: Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 15:635-641, 2001.

22. Stein RS, Greer JP, Goodman S, Kallianpur A, Ahmed MS, Wolff SN: High-dose therapy with autologous or allo-geneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant 23:227-233, 1999.

23. van Besien K, Sobocinski KA, Rowlings PA, et al.: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998.

24. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003.

25. Mandigers CM, Raemaekers JM, Schattenberg AV, et al.: Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. Br J Haematol 100:198-206, 1998.

26. Toze CL, Shepherd JD, Connors JM, et al.: Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 25:605-612, 2000.

27. Forrest DL, Thompson K, Nevill TJ, Couban S, Fernandez LA: Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma. Bone Marrow Transplant 29:973-978, 2002.

28. Yakoub-Agha I, Fawaz A, Folliot O, et al.: Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. Bone Marrow Transplant 30:229-234, 2002.

29. van Besien KW, Mehra RC, Giralt SC, et al.: Allogeneic bone marrow transplantation for poor-prognosis lym-

phoma: response, toxicity and survival depend on disease histology. Am J Med 100:299-307, 1996.

30. Chopra R, Goldstone AH, Pearce R, et al.: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:1690-1695, 1992.

31. Levine JE, Harris RE, Loberiza FR Jr, et al.: A comparison of allogeneic and autologous bone marrow transplant for lymphoblastic lymphoma. Blood 101:2476-2482, 2003.

32. Bureo E, Ortega JJ, Munoz A, et al.: Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 15: 353-359, 1995.

33. Ratanatharathorn V, Uberti J, Karanes C, et al.: Prospective comparative trial of autologous versus allo-geneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050-1055, 1994.

34. Schimmer AD, Jamal S, Messner H, et al.: Allogeneic or autologous bone marrow transplantation (BMT) for non- Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant 26:859-864, 2000.

35. Verdonck LF: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 34:129-136, 1999.

36. Lin TS, Elder PJ, Penza SI, et al.: Autologous stem cell transplants result in better 5-year overall, but not progression-free, survival than allogeneic transplants in patients with indolent non-Hodgkin's lymphoma. Blood 100 (suppl 1):644a, 2002. Abstract 2356.

37. Hosing C, Saliba RM, McLaughlin P, et al.: Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 14:737-744, 2003.

38. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonma-lignant hematologic diseases. Blood 91:756-763, 1998.

39. Khouri IF, Keating M, Korbling M, et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lym-phoid malignancies. J Clin Oncol 16:2817-2824, 1998.

40. McSweeney PA, Niederwieser D, Shizuru JA, et al.: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400, 2001.

41. Diaconescu R, Flowers C, Storer B, et al.: Morbidity and mortality with nonmyeloablative compared to nonmye-loablative conditioning before hematopoietic cell transplantation from HLA matched related donor. Blood 102: 77a, 2003. Abstract 261.

42. Robinson SP, Goldstone AH, Mackinnon S, et al.: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for

Blood and Bone Marrow Transplantation. Blood 100: 4310-4316, 2002.

43. Bertz H, Illerhaus G, Veelken H, Finke J: Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of highdose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 13: 135-139, 2002.

44. Seropian S, Bahceci E, Cooper DL: Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplant 32: 763-769, 2003.

45. Branson K, Chopra R, Kottaridis P, et al.: Role of non-myeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 20: 4022-4031, 2002.

46. Escalón MP, Champlin RE, Saliba RM, et al.: Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22: 2419-2423, 2004.

47. Corradini P, Tarella A, Olivieri A, et al.: Reduced-intensity conditioning followed by allografting of hematopoi-etic cells can produce clinical and molecular remissions in patients with poor-prognosis hematologic malignancies. Blood 99:75-82, 2002.

48. Khouri IF, Champlin RE: Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 31:22-26, 2004.

49. Faulkner RD, Craddock C, Byrne JL, et al.: BEAM-alem-tuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 103:428-434, 2004.

50. Robinson SP, Mackinnon S, Goldstone A, et al.: Higher than expected transplant-related mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely affects progression-free survival [abstract]. Blood 96(suppl 1):554a, 2000.

51. Chakraverty R, Peggs K, Chopra R, et al.: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071-1078, 2002.

52. Vandenberghe E, Ruiz De Elvira C, Loberiza FR, et al.: Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120:793-800, 2003.

53. Martinez C, Carreras E, Rovira M, et al.: Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 26:677-679, 2000.

54. Grigg A, Bardy P, Byron K, et al.: Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukemia and lymphoma. Bone Marrow Transplant 23:107-110, 1999.

55. Berdeja JG, Jones RJ, Zahurak MI, et al.: Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant 7:561-567, 2001.

56. Corradini P, Dodero A, Zallio F, et al.: Graft-versus-lym-phoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004.

57. Kolb HJ, Schattenberg A, Goldman JM, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995.

58. Porter DL, Roth MS, McGarigle C, et al.: lnduction of graft-versus-host disease as immunotherapy for relapsed chronic myelogenous leukemia. N Engl J Med 330: 100-106, 1994.

59. van Rhee F, Lin F, Cullis JO, et al.: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83: 3377-3383, 1994.

60. Collins R, Shpilberg O, Drobyski W, et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444, 1997.

61. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.: Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 18:3031-3037, 2000.

62. van Besien KW, de Lima M, Giralt SA, et al.: Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19:977-982, 1997.

63. Lush RJ, Haynes AP, Byrne J, et al.: Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-Campath (+/— fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy 3:203-210, 2001.

64. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM: Graft-versus-lym-phoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 32:1159-1163, 2003.

65. Press OW, Eary JF, Gooley T, et al.: A phase l/ll trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96: 2934-2942, 2000.

66. Gopal AK, Rajendran JG, Petersdorf SH, et al.: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002.

67. Cutler C, Antin JH: Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 34:471-476, 2004.

68. Schaap N, Schattenberg A, Bar B, et al.: lnduction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. Leukemia 15:1339-1346, 2001.

69. Baron F, Baudoux E, Fillet G, Beguin Y: Retrospective comparison of CD34-selected allogeneic peripheral blood stem cell transplantation followed by CD8-depleted donor lymphocyte infusions with unmanipu-lated bone marrow transplantation. Hematology 7:137-143, 2002.

70. Alyea EP, Canning C, Neuberg D, et al.: CD8+ cell depletion of donor lymphocyte infusions using cd8

monoclonal antibody-coated high-density microparti-cles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 34:123-128, 2004.

71. Pavletic SZ, Bociek RG, Foran JM, et al.: Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. Transplantation 76:877-881, 2003.

72. Chin KM, Miller KB, Chan GW, et al.: Favorable outcomes in matched unrelated donor allogeneic stem cell transplantation using a pentostatin/extracorporeal pho-topheresis based reduced intensity conditioning regimen. Blood 102(suppl 1), 2003. Abstract 1758.

73. Hamlin PA, Zelenetz AD, Kewalramani T, et al.: Age-adjusted International Prognostic Index predicts autolo-gous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102:1989-1996, 2003.

74. Moskowitz CH, Nimer SD, Glassman JR, et al.: The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant 23:561-567, 1999.

75. Chang CC, Bredeson C, Juckett M, Logan B, Keever-Taylor CA: Tumor load in patients with follicular lymphoma post stem cell transplantation may correlate with clinical course. Bone Marrow Transplant 32:287-291, 2003.

76. Liso A, Tiacci E, Binazzi R, et al.: Haploidentical peripheral-blood stem-cell transplantation for ALKpositive anaplastic large-cell lymphoma. Lancet Oncol 5: 127-128, 2004.

77. Bierman PJ, Molina A, Nelson G, et al.: Matched unrelated donor (MUD) allogeneic bone marrow transplantation for non-Hodgkin's lymphoma (NHL): results from the National Marrow Donor Program (NMDP). Proc Am Soc Clin Oncol 18:3a, 1999. Abstract 7.

78. Sykes M, Preffer F, McAfee S, et al.: Mixed lympho-haemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mis-matched bone-marrow transplantation. Lancet 353:1755-1759, 1999.

Chapter 66

DEFINITION OF REMISSION, PROGNOSIS, AND FOLLOW-UP IN FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

0 0

Post a comment